Hormonal
Once-weekly subcutaneous 2.4 mg semaglutide induces clinically meaningful, sustained double-digit weight loss (average ~15-16%) in adults with obesity or overweight, significantly outperforming previous pharmacotherapies and approaching results of metabolic surgery.
For adults with obesity or overweight plus a comorbidity, once-weekly 2.4 mg semaglutide is a highly effective treatment that produces an average 15-16% weight loss, which is significantly better than previous drugs and lifestyle changes alone. It requires a weekly injection, titrated up over 4 months to minimize side effects, alongside a modest calorie deficit and exercise. While GI side effects are common, they are usually manageable.
The results from the phase III STEP (Semaglutide treatment effect in people with obesity) clinical programme have shown that semaglutide provides clinically meaningful and sustained weight loss in ranges much higher than those achieved with previously available pharmacotheries... Those who received subcutaneous once-weekly 2.4 mg semaglutide had an average weight loss of up to 16%, which comes close – although not yet at the same level – to the performance of metabolic surgery.
Why this rating
Based on large-scale, randomized, double-blind, placebo-controlled phase III trials (STEP programme) with >4,500 participants.
Source
Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
Ides M. Colin et al. · touchREVIEWS in Endocrinology · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →